	US 12,453,692 B2
	Transdermal delivery composite using covalent organic framework and polymer
Hong Geun Ji, Gyeonggi-do (KR); Young Ah Park, Incheon (KR); Yu Jin Kang, Gyeonggi-do (KR); and Seung Yeon Son, Gyeonggi-do (KR)
Assigned to H&A PHARMACHEM CO., LTD, Gyeonggi-Do (KR)
Appl. No. 17/782,240
Filed by H&A PHARMACHEM CO., LTD, Gyeonggi-do (KR)
PCT Filed Nov. 12, 2020, PCT No. PCT/KR2020/015919 § 371(c)(1), (2) Date Jun. 3, 2022, PCT Pub. No. WO2021/112437, PCT Pub. Date Jun. 10, 2021.
Claims priority of application No. 10-2019-0161334 (KR), filed on Dec. 6, 2019.
Prior Publication US 2023/0018579 A1, Jan. 19, 2023
Int. Cl. A61K 8/73 (2006.01); A61K 8/85 (2006.01); A61K 9/70 (2006.01); A61Q 19/00 (2006.01)

CPC A61K 8/738 (2013.01) [A61K 8/736 (2013.01); A61K 8/85 (2013.01); A61K 9/7023 (2013.01); A61K 2800/57 (2013.01); A61Q 19/00 (2013.01)]

16 Claims

1. A composite for transdermal delivery comprising a cyclodextrin-based metal-organic framework (CD-MOF), a polymer, and an active ingredient,

wherein the cyclodextrin-based metal-organic framework is prepared from cyclodextrin and potassium hydroxide (KOH); and

wherein the polymer is selected from the group consisting of pullulan, polylactic acid, pullulan-poly-(L)-lactic acid, a triblock copolymer of polyethylene glycol (PEG)-polycaprolactone (PCL)-polyethylene glycol (PEG) and mixtures thereof.